An update on new orally administered contraceptives for women

  title={An update on new orally administered contraceptives for women},
  author={Anita L. Nelson},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2759 - 2772}
  • A. Nelson
  • Published 29 October 2015
  • Medicine
  • Expert Opinion on Pharmacotherapy
Introduction: The focus in contraception is shifting from oral contraceptives to more effective methods, such as implants and intrauterine devices. Generics are favored by third-party payors. As a result, potentially exciting developments in branded pills to increase safety or to reduce side effects may have gone unnoticed. Areas covered: This article reviews the features of each of the four new oral contraceptives that have been introduced in the United States and/or Europe in the last few… 

Trends in the use of oral contraceptives among adolescents and young women in Spain

There was a significant decrease in OC use from 2006 to 2012 among adolescents and young women living in Spain, and consumers of OCs were women who visited a gynaecologist more often and complied more with preventive measures such as Pap smear testing.

Review and Recommendations on Management of Adult Female Thalassemia Patients with Hypogonadism based on Literature Review and Experience of ICET-A Network Specialists

Doctors taking care of TM patients should have sound knowledge of the pathophysiology of hypogonadism in adult females with TM and know the potential effects of HRT including advantages and disadvantages of estrogen and progestins.

Environmental photochemistry of dienogest: phototransformation to estrogenic products and increased environmental persistence via reversible photohydration.

The outcomes reveal a dynamic fate and biological risk profile for dienogest that must also take into account the composition and endocrine activity of its transformation products, and illustrates the need for more holistic regulatory, risk assessment, and monitoring approaches for high potency synthetic pharmaceuticals and their bioactive transformation products.



Toward a new concept of “natural balance” in oral estroprogestin contraception

The focus on the estrogen component – which has not changed in 50 years – has yielded a new class of natural estrogen pills, and these recent achievements could represent a step forward in the evolution of COCs and pave the way for better safety.

An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest

The objective of the current review is to provide an overview of the development of COCs containing natural estrogen, highlighting past issues and challenges faced by earlier formulations, as well as the current status and future directions.

Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America.

A COC with E2V and DNG was shown to provide effective contraception in women aged 18-35 years in North America.

Metabolic effects of contraceptive steroids

The lower metabolic impact of estradiol-based combinations may result in an improved safety profile, but large surveillance studies are warranted to confirm this plausible hypothesis.

Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill

The aim of this review is to define the role of the combined dienogest (DNG)/estradiol valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and pharmacological effects and clinical

Effectiveness of long-acting reversible contraception.

The effectiveness of long-acting reversible contraception is superior to that of contraceptive pills, patch, or ring and is not altered in adolescents and young women.

Estradiol valerate and dienogest: a new approach to oral contraception

Estradiol valerate plus dienogest (E2V/DNG) is now available in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing approach along with a short two-day hormone-free interval.

Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest

Use of E2V/DNG for six months has led to significant reductions in heavy menstrual bleeding with an average 65% reduction in mean blood loss, and significant improvements in hematologic indicators have been shown.

Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest

After 20 cycles of treatment, an oral contraceptive containing E2V and DNG is safe and effective to transform the endometrium into a secretory/inactive or atrophic status, and exhibits no deleterious effects on endometrial histology in women aged 18–50 years.